(¿Â¶óÀÎ)´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¦ 27Â÷ Ãß°èÇмú´ëȸ : 2021-10-30±³À°ÀÏÀÚ : 2021-10-30
±³À°Àå¼Ò : ¿Â¶óÀÎ
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ)´ëÇѺÎÀÎÁ¾¾çÇÐȸ Á¦ 27Â÷ Ãß°èÇмú´ëȸÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
´ã´çÀÚ : ÇѼ¼¹Ì
¿¬¶ôó : 02-512-0044
À̸ÞÀÏ :
office@sgo.or.kr ±³À°Á¾·ù : »êºÎÀΰú
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 45ºÐ
¼¼ºÎ¼ö°·á : 60,000¿ø
ºñ°í Àü¹®ÀÇ 60,000 Àü°øÀÇ 45,000 ÀϹÝÀÇ,¿¬±¸¿ø,°£È£»ç 30,000 ÁÂÀå,¿¬ÀÚ,¸¸65¼¼ÀÌ»ó ¹«·á
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 10-30 ¿Â¶óÀÎ 08:50~09:00 Opening Remarks ±è¿µÅÂ(´ëÇѺÎÀÎÁ¾¾çÇÐȸ ȸÀå)
±âŸ 10-30 ¿Â¶óÀÎ 09:00~09:05 Á¦5ȸ ºÎÀÎÁ¾¾çÀÇÇлó, JGO Best reviewer ½Ã»ó½Ä ()
±³À°½Ã°£ 10-30 ¿Â¶óÀÎ 09:05~09:10 ºÎÀÎÁ¾¾çÀÇÇлó Çмú´ë»ó ¼ö»óÀÚ ¹ßÇ¥ ¼ö»óÀÚ()
±³À°½Ã°£ 10-30 ¿Â¶óÀÎ 09:10~09:15 ºÎÀÎÁ¾¾çÀÇÇлó ÀþÀºÀÇÇÐÀÚ ¼ö»óÀÚ ¹ßÇ¥ ¼ö»óÀÚ()
±âŸ 10-30 ¿Â¶óÀÎ 09:15~09:20 ¸í¿¹È¸¿øÁõ ¼ö¿© Daisuke Aok(Keio University, Japan)
±³À°½Ã°£ 10-30 ¿Â¶óÀÎ 09:20~09:40 SOC-1 (Ovarian Cancer) Rongyu Zang(Fudan University Zhongshan Hospital, China)
Åä·Ð 10-30 ¿Â¶óÀÎ 09:40~09:50 Designated discussion ÀÌÀ¯¿µ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 10-30 ¿Â¶óÀÎ 09:50~10:10 KEYNOTE-775 (Endometrial Cancer ) Vicky Makker(Memorial Sloan Kettering Cancer Center, USA)
Åä·Ð 10-30 ¿Â¶óÀÎ 10:10~10:20 Designated discussion ±è¹Ì°æ(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 10-30 ¿Â¶óÀÎ 10:20~10:40 KEYNOTE-826 (Cervical Cancer) Nicoletta Colombo(Istituto Europeo di Oncologia, Italia)
Åä·Ð 10-30 ¿Â¶óÀÎ 10:40~10:50 Designated discussion ±èÈñ½Â(¼¿ïÀÇ´ë)
ÈÞ½Ä 10-30 ¿Â¶óÀÎ 10:50~11:00 Break ()
±³À°½Ã°£ 10-30 ¿Â¶óÀÎ 11:00~11:15 Do you think First-line maintenance to all patients with ovarian cancer? - Pros À̼ºÁ¾(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 10-30 ¿Â¶óÀÎ 11:15~11:30 Do you think First-line maintenance to all patients with ovarian cancer? - Cons ¹Ú±Ç¿À(ºÎ»êÀÇ´ë Á¾¾ç³»°ú)
±³À°½Ã°£ 10-30 ¿Â¶óÀÎ 11:30~11:50 Selection of surgery in patients with recurrent ovarian cancer À̸¶¸®¾Æ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10-30 ¿Â¶óÀÎ 11:50~12:00 Case study ÃÖ¹Îö(Â÷ÀÇ´ë)
±³À°½Ã°£ 10-30 ¿Â¶óÀÎ 12:00~12:20 Molecular classification of endometrial cancer: selecting adjuvant therapy È«ÁøÈ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 10-30 ¿Â¶óÀÎ 12:20~12:30 Case study ³²ÀºÁö(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10-30 ¿Â¶óÀÎ 12:30~12:50 Real-world ovarian cancer Niraparib patient case studies Richard T Penson MD MRCP(Medicine Harvard Medical School)
±³À°½Ã°£ 10-30 ¿Â¶óÀÎ 12:50~13:10 ONBEVZI: The Arrival of Bevacizumab Biosimilar in Gynecologic Cancer ¼µ¿ÈÆ(¼¿ïÀÇ´ë)
½Ä»ç 10-30 ¿Â¶óÀÎ 13:10~13:50 Lunch ()
±âŸ 10-30 ¿Â¶óÀÎ 13:50~14:05 ºÎÀÎ¾Ï ¼ö¼úµ¿ÀǼ °øûȸ-°³¿ä ¹× ¾ÏÁ¾º° µ¿ÀǼ ¹ßÇ¥ ½É»çÀ§¿øȸ(ºÎÀÎÁ¾¾çÇÐȸ)
±âŸ 10-30 ¿Â¶óÀÎ 14:05~14:20 Discussion ()
±³À°½Ã°£ 10-30 ¿Â¶óÀÎ 14:20~14:40 Relevance of Artificial intelligence-Surgery Á¤Ã¢¿í(¼¿ïÀÇ´ë ºñ´¢ÀÇÇаú)
±³À°½Ã°£ 10-30 ¿Â¶óÀÎ 14:40~15:00 Relevance of Artificial intelligence-Radiology ±èÈÖ¿µ(¿¬¼¼ÀÇ´ë ¿µ»óÀÇÇаú)
±³À°½Ã°£ 10-30 ¿Â¶óÀÎ 15:00~15:20 Relevance of Artificial intelligence-Pathology Á¤¿ä¼Á(°¡Å縯ÀÇ´ë º´¸®°ú)
Åä·Ð 10-30 ¿Â¶óÀÎ 15:20~15:40 Designated discussion À̽ÅÈ/°øÅ¿í(¿ï»êÀÇ´ë/¾ÆÁÖÀÇ´ë)
ÈÞ½Ä 10-30 ¿Â¶óÀÎ 15:40~15:55 Break ()
±³À°½Ã°£ 10-30 ¿Â¶óÀÎ 15:55~16:10 Domestic approach to HRD testing Á¶ÀºÇØ(³ì½ÊÀÚÁö³ð¿¬±¸¼Ò)
Åä·Ð 10-30 ¿Â¶óÀÎ 16:10~16:20 Designated discussion ÀÓ¸íö(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 10-30 ¿Â¶óÀÎ 16:20~16:40 Management of side effects through patients education ±è¹Î±Ô(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 10-30 ¿Â¶óÀÎ 16:40~16:50 Case study ½É½ÂÇõ(°Ç±¹ÀÇ´ë)
±³À°½Ã°£ 10-30 ¿Â¶óÀÎ 16:50~17:10 Breaking bad news À¯Àº½Â(°í·Á»çÀ̹ö´ë)
±³À°½Ã°£ 10-30 ¿Â¶óÀÎ 17:10~17:30 End of life care ÀÓ°¡¿ø(µ¿±¹ÀÇ´ë)
±âŸ 10-30 ¿Â¶óÀÎ 17:30~17:50 Closing Remarks & Á¤±âÃÑȸ ()